Ann Janssens

6PUBLICATIONS
41CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 30, 2026
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Moritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht

|Oct 30, 2025
Overall survival outcomes with first-line continuous ibrutinib and fixed-duration ibrutinib-venetoclax treatments in patients with chronic lymphocytic leukemia: Comparison with an age-matched European population.

Paolo Ghia, Loic Ysebaert, Ann Janssens

|Aug 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

Othman Al-Sawaf, Moritz Fürstenau, Adam Giza

|Apr 18, 2025
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.

Carsten U Niemann, Julie Dubois, Kazem Nasserinejad

|Sep 18, 2023
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.

Loretta J Nastoupil, Georg Hess, Miguel A Pavlovsky

|May 12, 2023
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.

Moritz Fürstenau, Yvonne J Thus, Sandra Robrecht

Pageof 1

Frequent Collaborators

4 joint publications

Caspar da Cunha-Bang

4 joint publications

Arnon P Kater

4 joint publications

Carsten Utoft Niemann

3 joint publications

Moritz Fürstenau